DCVCBio's profile picture. Venture Capital Funds investing in companies solving big life science problems with big compute

DCVC Bio

@DCVCBio

Venture Capital Funds investing in companies solving big life science problems with big compute

Pinned

We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more! bit.ly/3ZRmdpo


DCVC Bio reposted

Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025! This award recognizes the companies and innovations pushing science forward to transform the field of life…

OrcaBio's tweet image. Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025!

This award recognizes the companies and innovations pushing science forward to transform the field of life…

DCVC Bio reposted

Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies. Read more in the press release: bit.ly/4q1Uzkw #celltherapy #hematology #oncology

OrcaBio's tweet image. Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies.

Read more in the press release: bit.ly/4q1Uzkw

#celltherapy #hematology #oncology

DCVC Bio reposted

Augmented RNA reality is emerging! @creyonbio has the ability to program­mat­i­cally engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock a huge range of therapeutic advances👇 dcvc.com/news-insights/…


DCVC Bio reposted

Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare

creyonbio's tweet image. Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/
#BiotechNews #AIinHealthcare

How is @MycoWorksInc scaling its production and simultaneously doing R&D for new mycelium materials? Find out from CEO Matthew Scullin in a great @axios piece from @katiefehren 👇 axios.com/pro/climate-de…


Reishi is here! 🎉 Very exciting progress from @MycoWorksInc, which continues to push the boundaries of sustainable design 👇 fashionunited.in/news/business/…


When one of your portfolio cos is moving toward commer­cial­izing what may be the most conse­quen­tial cancer therapeutic ever, you’re allowed to take a minute to feel excited. That's how we feel today having co-led @UmojaBiopharma's $100m Series C! 🍾 dcvc.com/news-insights/…


DCVC Bio reposted

We're thrilled to announce that thanks to the most forward-looking investors on the planet, we’ve raised over $700 million for a healthier planet and healthier lives, bringing our total funding closed over the last 2.5 years to over $1.6 billion 🌎🧬🌾 bit.ly/4eHLNl9


DCVC Bio reposted

Our second annual Deep Tech Opportunities Report is here, offering an extended look at deep tech and how we believe it can help build a future of abundance and resilience. We hope you enjoy it — and the possi­bil­i­ties it signals. dcvc.com/news-insights/…


Great in-depth coverage from @ADeAngelis_bio @statnews about our announcement of DCVC Bio III: $400 million in fresh capital to continue backing the next generation of companies building breakthrough data-driven life-science businesses.👇 bit.ly/47Q3qgw


DCVC Bio reposted

Please welcome Serge Messerlian @DCVC, to our Board of Directors! With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. brnw.ch/21wMua9

creyonbio's tweet image. Please welcome Serge Messerlian @DCVC, to our Board of Directors!

With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. 

brnw.ch/21wMua9

DCVC Bio reposted

"Digital twins are the future of medicine. They basically replace our entire medical system; you basically turn medicine into a predictive science, you run experiments, and you optimize patients' treatments" — @charleskfisher in the @ZDNET article, "How digital twins could save…


DCVC Bio reposted

"The days of promising technology are behind us - be a builder." hubs.la/Q02LYsHZ0


DCVC Bio reposted

🌐 According to the @WHO, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #digitaltwin generators for both…

UnlearnAI's tweet image. 🌐 According to the @WHO, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #digitaltwin generators for both…
UnlearnAI's tweet image. 🌐 According to the @WHO, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #digitaltwin generators for both…

DCVC Bio reposted

Our CEO @chrihart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry. Read more in @NAInsights: insights.bio/nucleic-acid-i…

creyonbio's tweet image. Our CEO @chrihart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry. 

Read more in @NAInsights: insights.bio/nucleic-acid-i…

Loading...

Something went wrong.


Something went wrong.